Nuwellis Stockholders Approve All Proposals at Special Meeting
Nuwellis (Nasdaq: NUWE), a medical technology company specializing in fluid management, announced that stockholders approved all proposals at their Special Meeting. The key approvals include: warrant exercise authorization for the June 2025 financing, an increase in authorized common stock from 100 million to 200 million shares, and authorization for a potential reverse stock split at a ratio between 1-for-5 and 1-for-70.
The reverse split authorization aims to maintain Nasdaq listing compliance, while the other measures are designed to enhance financial flexibility and support strategic growth initiatives.
Nuwellis (Nasdaq: NUWE), un'azienda di tecnologia medica specializzata nella gestione dei fluidi, ha annunciato che gli azionisti hanno approvato tutte le proposte durante l'Assemblea Straordinaria. Le approvazioni principali includono: l'autorizzazione all'esercizio dei warrant per il finanziamento di giugno 2025, un aumento del capitale sociale autorizzato da 100 milioni a 200 milioni di azioni e l'autorizzazione a un potenziale split azionario inverso con un rapporto compreso tra 1 a 5 e 1 a 70.
L'autorizzazione allo split inverso mira a mantenere la conformit脿 ai requisiti di quotazione Nasdaq, mentre le altre misure sono pensate per aumentare la flessibilit脿 finanziaria e supportare iniziative strategiche di crescita.
Nuwellis (Nasdaq: NUWE), una empresa de tecnolog铆a m茅dica especializada en la gesti贸n de fluidos, anunci贸 que los accionistas aprobaron todas las propuestas en su Junta Especial. Las aprobaciones clave incluyen: autorizaci贸n para el ejercicio de warrants para la financiaci贸n de junio de 2025, un aumento del capital social autorizado de 100 millones a 200 millones de acciones, y la autorizaci贸n para una posible consolidaci贸n inversa de acciones en una proporci贸n entre 1 por 5 y 1 por 70.
La autorizaci贸n para la consolidaci贸n inversa tiene como objetivo mantener el cumplimiento con la cotizaci贸n en Nasdaq, mientras que las otras medidas est谩n dise帽adas para mejorar la flexibilidad financiera y apoyar iniciativas estrat茅gicas de crecimiento.
Nuwellis (雮橃姢雼�: NUWE)電� 觳挫暋 甏�毽棎 韸鬼檾霅� 鞚橂旮办垹 須岇偓搿�, 欤检＜霌れ澊 韸闺硠須岇潣鞐愳劀 氇摖 鞎堦贝鞚� 鞀轨澑頄堧嫟瓿� 氚滍憸頄堨姷雼堧嫟. 欤检殧 鞀轨澑 靷暛鞐愲姅 2025雲� 6鞗� 鞛愱笀 臁半嫭鞚� 鞙勴暅 鞗岆煱韸� 頄夓偓 鞀轨澑, 鞀轨澑霅� 氤错喌欤� 欤检嫕 靾橂ゼ 1鞏� 欤检棎靹� 2鞏� 欤茧 歃濌皜, 攴鸽Μ瓿� 1雽� 5鞐愳劀 1雽� 70 靷澊鞚� 牍勳湪搿� 鞐＜鞁� 攵勴暊 臧�電レ劚鞐� 雽�頃� 鞀轨澑 霌膘澊 韽暔霅╇媹雼�.
鞐＜鞁� 攵勴暊 鞀轨澑鞚� 雮橃姢雼� 靸侅灔 鞖旉贝鞚� 鞙犾頃橁赴 鞙勴暅 瓴冹澊氅�, 旮绊儉 臁办箻電� 鞛 鞙犾棸靹膘潉 雴掛澊瓿� 鞝勲灥鞝� 靹膘灔 鞚措媹靺旐嫲敫岆ゼ 歆�鞗愴晿旮� 鞙勴暣 靹り硠霅橃棃鞀惦媹雼�.
Nuwellis (Nasdaq : NUWE), une entreprise de technologie m茅dicale sp茅cialis茅e dans la gestion des fluides, a annonc茅 que les actionnaires ont approuv茅 toutes les propositions lors de leur assembl茅e extraordinaire. Les approbations cl茅s comprennent : l'autorisation d'exercer les bons de souscription pour le financement de juin 2025, une augmentation du capital social autoris茅 de 100 millions 脿 200 millions d'actions, et l'autorisation d'une 茅ventuelle fusion invers茅e d'actions 脿 un ratio compris entre 1 pour 5 et 1 pour 70.
L'autorisation de la fusion invers茅e vise 脿 maintenir la conformit茅 avec la cotation Nasdaq, tandis que les autres mesures sont con莽ues pour renforcer la flexibilit茅 financi猫re et soutenir les initiatives strat茅giques de croissance.
Nuwellis (Nasdaq: NUWE), ein Medizintechnikunternehmen, das sich auf Fl眉ssigkeitsmanagement spezialisiert hat, gab bekannt, dass die Aktion盲re auf ihrer au脽erordentlichen Hauptversammlung alle Vorschl盲ge genehmigt haben. Zu den wichtigsten Genehmigungen geh枚ren: die Erm盲chtigung zur Aus眉bung von Warrants f眉r die Finanzierung im Juni 2025, eine Erh枚hung des genehmigten Stammkapitals von 100 Millionen auf 200 Millionen Aktien sowie die Genehmigung einer m枚glichen Aktienzusammenlegung im Verh盲ltnis von 1:5 bis 1:70.
Die Genehmigung der Aktienzusammenlegung soll die Einhaltung der Nasdaq-Listing-Anforderungen sicherstellen, w盲hrend die anderen Ma脽nahmen darauf abzielen, die finanzielle Flexibilit盲t zu erh枚hen und strategische Wachstumsinitiativen zu unterst眉tzen.
- None.
- Potential significant share dilution from warrant exercises
- Possible reverse split indicates stock price challenges
- Risk of Nasdaq delisting without implementing reverse split
MINNEAPOLIS , Aug. 04, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on fluid management, today announced that stockholders approved all proposals presented at the company鈥檚 Special Meeting of Stockholders, held virtually earlier today.
Each proposal was designed to enhance the company鈥檚 financial flexibility and support ongoing strategic growth. The approved items include:
Warrant Exercise Proposal 鈥� Stockholders approved the issuance of shares of common stock pursuant to the exercise of warrants sold in the company鈥檚 June 10, 2025 financing, in accordance with Nasdaq Listing Rule 5635(d). This approval enables Nuwellis to fully access the committed capital from the offering.
Authorized Shares Increase Proposal 鈥� Stockholders approved an amendment to the Company鈥檚 Certificate of Incorporation to increase the number of authorized shares of common stock from 100 million to 200 million.
Reverse Split Proposal 鈥� Stockholders approved an amendment to the Company鈥檚 Certificate of Incorporation authorizing a reverse stock split at a ratio between 1-for-5 and 1-for-70, to be enacted at the discretion of the Board of Directors, if necessary, to maintain Nasdaq listing compliance.
鈥淲e appreciate the strong support from our stockholders,鈥� said John Erb, Chief Executive Officer of Nuwellis. 鈥淭hese approvals mark important progress toward strengthening our capital position and ensuring we have the flexibility to execute our long-term strategy.鈥�
Final voting results will be included in a Form 8-K to be filed with the U.S. Securities and Exchange Commission.
For more information, visit .
About Nuwellis Nuwellis, Inc. (Nasdaq: NUWE) is a medical device company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The company is focused on commercializing the Aquadex SmartFlow庐 system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, with a wholly owned subsidiary in Ireland. For more information visit www.nuwellis.com or visit us on LinkedIn or X, formerly known as Twitter.
About the Aquadex SmartFlow庐 System The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.
Forward-Looking Statements Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2025 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether due to new information, future events or otherwise.
For further information, please contact:
Investor Relations:
Robert Scott
Chief Financial Officer
Media Contact:
Leah McMullen
Director of Communications
FAQ
What proposals did Nuwellis (NUWE) stockholders approve at the August 2025 Special Meeting?
What is the purpose of Nuwellis (NUWE) reverse stock split authorization?
How many authorized shares will Nuwellis (NUWE) have after the increase?
What was the purpose of Nuwellis (NUWE) Special Meeting in August 2025?
